Quarterly ResultAug 13, 2026, 04:45 PM
Vivani Medical Q2 Net Loss $6.4M; NPM-139 Trial Dosed, Novo Nordisk Deal
AI Summary
Vivani Medical, Inc. reported its second quarter 2026 financial results, showing a reduced net loss of $6.4 million compared to $7.1 million in the prior year. The company highlighted significant business progress, including the successful dosing of all participants in its SLIM-1™ Phase 1 trial for NPM-139, with top-line data expected in November 2026. Vivani also announced a non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and its NanoPortal™ technology, alongside the anticipated Q3 2026 completion of the Cortigent-ClearOne merger, which will establish Cortigent as an independent publicly traded entity.
Key Highlights
- Q2 2026 net loss decreased to $6.4 million from $7.1 million in Q2 2025.
- Cash, cash equivalents, and restricted cash totaled $20.8 million as of June 30, 2026.
- All participants successfully dosed in SLIM-1™ Phase 1 trial for NPM-139; top-line data expected November 2026.
- Entered non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and NanoPortal™ technology.
- Cortigent-ClearOne merger anticipated to close in Q3 2026, establishing Cortigent as a separate public company.
- Research and development expense decreased to $4.5 million in Q2 2026 from $4.8 million in Q2 2025.
- General and administrative expense decreased to $2.4 million in Q2 2026 from $2.7 million in Q2 2025.
- Net loss per common share improved to $(0.07) in Q2 2026 from $(0.12) in Q2 2025.
Price Impact
More from VANI